Uprosertib/Trametinib Dimethyl Sulfoxide

优普色替/二甲基亚砜曲美替尼

Report date: 2024/07/04 18:02:47

Base Information

Drug NameUprosertib/Trametinib Dimethyl Sulfoxide
Drug Alias NameUprosertib/Trametinib优普色替-二甲基亚砜曲美替尼优普色替+二甲基亚砜曲美替尼Trametinib Dimethyl Sulfoxide/Uprosertib乌洛舍替/二甲基亚砜曲美替尼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitorsDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors +[5] 
TargetsSerine/threonine-protein kinase AKT2Dual specificity mitogen-activated protein kinase kinase 2Serine/threonine-protein kinase AKT3 +[5] 
Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes UprosertibTrametinib Dimethyl Sulfoxide
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesNational Cancer Institute
Active IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A